CD4+/CD25+ cells

PreclinicalBiologic

MMasonic Cancer Center, University of Minnesota

CD4+/CD25+ cells is one of 5 biologic programs targeting Hematological Malignancy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignancyTerminated

Hematological MalignancyPreclinical

Terminated

Competition

Competitive Landscape

6 competitors in Hematological Malignancy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 3

Anti-Human Thymoglobulin

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1

1 4

CTA101

TThe First Affiliated Hospital with Nanjing Medical University

Phase 1

1 5

CD4+/CD25+ cells

MMasonic Cancer Center, University of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematological Malignancy1 trial

Stem Cell Transplant for Hematological Malignancy

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00176930·330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD4+/CD25+ cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD4+/CD25+ cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD4+/CD25+ cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMasonic Cancer Center, University of Minnesota

CD4+/CD25+ cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematological Malignancy1 trial

References

Drug Info

Quick Facts

Related News